Myconormin (Terbinafine Hydrochloride)

Terbinafine Hydrochloride, the active ingredient in Myconormin, is a allylamine antifungal presented as an oral dosage form for systemic use. It is indicated for the treatment of dermatophyte infections of the skin, hair and nails in adult patients. It is commonly prescribed for infections such as athlete’s foot, ringworm of the body, jock itch and fungal nail disease, providing a convenient oral option for patients.

GNH USA supplies Myconormin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics.

Myconormin (terbinafine) is an allylamine antifungal that targets dermatophyte infections of the skin, hair and nails.

- Tinea pedis: resolves foot fungal infection, relieving itching and scaling. - Tinea corporis: treats body ringworm, clearing erythematous lesions. - Tinea cruris: eliminates jock itch, reducing redness and discomfort. - Onychomycosis: improves fungal nail infection, promoting normal nail growth.

Adverse reactions may occur with oral terbinafine therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal upset: nausea, abdominal pain or dyspepsia. - Skin rash: pruritic or erythematous lesions. - Taste disturbance: altered or loss of taste perception. - Elevated liver enzymes: mild, transient increase. - Diarrhea: loose stools without blood.

Serious or Rare Side Effects: - Hepatotoxicity: jaundice, hepatitis or liver failure. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood dyscrasias: neutropenia, thrombocytopenia or anemia. - Peripheral neuropathy: numbness or tingling in extremities. - Visual disturbances: blurred vision or photophobia.

Patients should be evaluated for safety considerations before initiating therapy.

- Assess liver function: obtain baseline hepatic enzymes and monitor periodically. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Monitor renal function: adjust dose in severe renal impairment. - Review concomitant medications: watch for interactions that affect terbinafine metabolism. - Caution in elderly: consider comorbidities and polypharmacy. - Store at room temperature: keep below 25 °C in the original pack, protect from moisture.

Terbinafine may interact with several medicines; interaction severity varies.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase terbinafine plasma levels. - Rifampin: may reduce terbinafine exposure, compromising efficacy. - Cimetidine: can raise terbinafine concentrations, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for potential anticoagulant effect alteration. - Oral contraceptives: may reduce hormonal efficacy, advise backup contraception. - Azole antifungals (e.g., itraconazole): additive hepatotoxic risk. - Statins: observe for increased muscle toxicity. - Antidepressants metabolized by CYP3A4: assess for altered drug levels.